Herantis Pharma Oyj Stock EBITDA
| HRTIS Stock | EUR 1.49 0.07 4.49% |
Herantis Pharma Oyj fundamentals help investors to digest information that contributes to Herantis Pharma's financial success or failures. It also enables traders to predict the movement of Herantis Stock. The fundamental analysis module provides a way to measure Herantis Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Herantis Pharma stock.
Herantis |
Herantis Pharma Oyj Company EBITDA Analysis
Herantis Pharma's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Herantis Pharma EBITDA | (9.74 M) |
Most of Herantis Pharma's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Herantis Pharma Oyj is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, Herantis Pharma Oyj reported earnings before interest,tax, depreciation and amortization of (9.74 Million). This is 101.11% lower than that of the Pharmaceuticals sector and 109.72% lower than that of the Health Care industry. The ebitda for all Finland stocks is 100.25% higher than that of the company.
Herantis EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Herantis Pharma's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Herantis Pharma could also be used in its relative valuation, which is a method of valuing Herantis Pharma by comparing valuation metrics of similar companies.Herantis Pharma is currently under evaluation in ebitda category among its peers.
Herantis Fundamentals
| Return On Equity | -13.37 | |||
| Return On Asset | -0.6 | |||
| Current Valuation | 25.86 M | |||
| Shares Outstanding | 16.91 M | |||
| Shares Owned By Insiders | 31.52 % | |||
| Shares Owned By Institutions | 32.60 % | |||
| Price To Earning | (7.20) X | |||
| Price To Book | 15.17 X | |||
| Gross Profit | 90 K | |||
| EBITDA | (9.74 M) | |||
| Net Income | (12.77 M) | |||
| Cash And Equivalents | 7.86 M | |||
| Cash Per Share | 0.81 X | |||
| Total Debt | 6.29 M | |||
| Debt To Equity | 0.95 % | |||
| Current Ratio | 1.54 X | |||
| Book Value Per Share | 0.11 X | |||
| Cash Flow From Operations | (9.93 M) | |||
| Earnings Per Share | (1.25) X | |||
| Target Price | 2.1 | |||
| Number Of Employees | 13 | |||
| Beta | 0.51 | |||
| Market Capitalization | 39.58 M | |||
| Total Asset | 7.76 M | |||
| Retained Earnings | (27 M) | |||
| Working Capital | 5 M | |||
| Current Asset | 6 M | |||
| Current Liabilities | 1000 K | |||
| Z Score | -3.9 | |||
| Net Asset | 7.76 M |
About Herantis Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Herantis Pharma Oyj's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Herantis Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Herantis Pharma Oyj based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Herantis Stock
Herantis Pharma financial ratios help investors to determine whether Herantis Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Herantis with respect to the benefits of owning Herantis Pharma security.